Citations

Clear

144 citation(s) found for "Hopkins, David".

Convalescent Plasma Restores Viral Clearance After Anti‐Spike Monoclonal Antibody Failure in Immunocompromised COVID‐19 Patients: A Systematic Review and Meta‐Analysis of Individual Patient Data
Focosi, Daniele , Aiello, Tommaso Francesco , Cruciani, Mario , D’Abramo, Alessandra , Marco, Patrizia De, Garcia‐Vidal, Carolina, Glingani, Claudia, Hueso, Thomas , Richier, Quentin , Tomisti, Luca , Weinbergerova, Barbora, Zani, Matteo , Zaremba, Solomiia , Cruciani, Mario , D'Abramo, Alessandra , De Marco, Patrizia , Gachoud, David , Hueso, Thomas , Joyner, Michael J , Lacombe, Karine , Mengoli, Carlo , Nicastri, Emanuele , Richier, Quentin , Rufer, Nathalie , Senefeld, Jonathon W , Sullivan, David J , Zaremba, Solomiia , Franchini, Massimo , Focosi, Daniele , Casadevall, Arturo , García‐Vidal, Carolina , Joyner, Michael J. , Mengoli, Carlo , Senefeld, Jonathon W. , Shoham, Shmuel , Sullivan, David , Weinbergerová, Barbora , Franchini, Massimo

Mayo Clinic

Reviews in Medical Virology | July 31, 2026 | Volume: 36 | Issue: 5 | Pages: No page available

10.1002/rmv.70185 | PMID 42536824 Get It

ABSTRACT Anti‐Spike monoclonal antibodies (mAbs) progressively lost efficacy during the COVID‐19 pandemic due to the emergence and predominance of resistant SARS‐CoV‐2 variants. By contrast, high‐titre COVID‐19 convalescent plasma (CCP) collected from vaccinated donors recently recovered from infection provides a polyclonal source of antibodies that remains effective in clearing SARS‐CoV‐2 in immunosuppressed patients, unable to mount an adequate immune response against the virus. We conducted a systematic review and individual participant data meta‐analysis to examine the effect of CCP in immunocompromised patients persistently positive for SARS‐CoV‐2 viraemia following mAb therapy, and to evaluate possible biological factors associated with a favourable outcome. Electronic databases were searched for studies published from January 2020 to January 2026. All studies including eligible cases were considered in the systematic review. Unpublished cases were also collected from investigators of the selected studies. The protocol was registered at PROSPERO (CRD420251142891). Forty‐seven cases (30 cases from 12 published studies and 17 unpublished cases) were included. In 33 out of 47 patients (70.2%) with a mAb‐resistant infection, SARS‐CoV‐2 clearance occurred following CCP transfusion, with a mean of 2.7 CCP units administered. In logistic regression, total CCP volume transfused was positively associated with SARS‐CoV‐2 clearance. In conclusion, CCP transfusion was associated with SARS‐CoV‐2 clearance in persistently positive immunocompromised patients following failure of anti‐Spike mAb therapy.
Establishing a Specialty Bipolar Clinic: The National Network of Depression Centers Consensus Recommendations
Schneck, Christopher D. , Bond, David J., Burdick, Katherine E. , Frye, Mark A. , Huber, Rebekah S., Mahon, Pamela, McInnis, Melvin G., Nurnberger, John, Öngür, Döst , Ostacher, Michael J., Parikh, Sagar V. , Raj, Kristin S. , Schweizer, Barbara , Soares, Jair C., Sullivan, Aimee E. , Suppes, Trisha , Zandi, Peter P. , Ostacher, Michael J. , Bond, David J. , Burdick, K E , Frye, Mark , Sperry, Sarah , Zandi, Peter P , DePaulo, J Raymond , Bond, David J , Ostacher, Michael J , Almeida, Jorge , Goes, Fernando , Huber, Rebekah S. , Machado‐Vieira, Rodrigo , Mahon, Pamela B. , McInnis, Melvin G. , Nurnberger, John I , Respino, Matteo , Soares, Jair C. , Sperry, Sarah H. , Veldić, Marin

Mayo Clinic

Bipolar Disorders | July 10, 2026 | Volume: 28 | Issue: 5 | Pages: No page available

10.1111/bdi.70154 | PMID 42429592 Get It

ABSTRACT Objective To provide expert recommendations for the development of a specialty bipolar clinic that promotes best clinical practices for the delivery of safe and effective care. Methods Members of the National Network of Depression Centers (NNDC) Bipolar Clinics Work Group met in a series of 1‐h monthly video calls over 18 months to discuss all aspects of their respective institution's bipolar clinics, including services provided, administrative processes, staffing models, characteristics of patients treated, patient volumes, finances, and research. The group also invited psychiatrists from outside of the NNDC who ran large bipolar clinics to contribute their thoughts and experiences on the subject. In addition, the NNDC sent a 20‐question survey to all 27 sites asking clinic directors specific questions about their bipolar clinics, if applicable. Further meetings and discussions incorporating results from the survey took place to produce a comprehensive set of recommendations. Results Twenty‐one of 27 NNDC sites (81%) responded to the survey. Twelve of 21 (57%) sites had a specific bipolar clinic, and another 4 (19%) were looking to start one. Clinics were based in university settings. The meetings, clinic survey, and discussions resulted in 10 recommendations describing services and operations for bipolar specialty clinics. Conclusions Given the complexity of bipolar disorder, specialty clinics are important to enhance care. Clinics with a wide array of services that include consultation, medication management, bipolar‐specific psychotherapies, and patient/family psychoeducation provide the most comprehensive care. Challenges to these clinics include maintaining ongoing patient access as well as ensuring long‐term financial stability.
Toward autonomous robotic-assisted and microrobotic surgery
Yang, Sungyun , Kang, Byung Ha , Min, Hyeongho , Wachs, Juan , Alambeigi, Farshid , Desai, Jaydev P. , Yaeger, Kurt , Anderson, Katherine, Kuntz, Alan , Alterovitz, Ron , Webster, Robert J. , Hata, Nobuhiko , Reisenauer, Janani , Clinch, McKenna, Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Kim, Peter C., Huang, Alex S. , Zhang, Hao F. , Riviere, Cameron N. , Henderson, Eric R. , Yip, Michael C. , Dong, Xiaoguang , Wollin, Daniel , Mair, Lamar O. , Karpelson, Michael , Wood, Robert J. , Cohen, Itai , Strano, Michael S. , Wachs, Juan P , Dupont, Pierre E , Yaeger, Kurt , Anderson, Katherine , Kuntz, Alan , Alterovitz, Ron , Webster, Robert J , Hata, Nobuhiko , Reisenauer, Janani S , Clinch, McKenna , Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Sun, Cheng , Zhang, Hao F , Riviere, Cameron N , Henderson, Eric R , Yip, Michael , Dong, Xiaoguang , Wollin, Daniel A , Gracias, David H , Mair, Lamar O , Karpelson, Michael , Wood, Robert J , Cohen, Itai , Strano, Michael S

Mayo Clinic

Science Advances | July 1, 2026 | Volume: 12 | Issue: 27 | Pages: No page available

10.1126/sciadv.aec4197 | PMID 42384805 Get It

Autonomous robotic-assisted surgery (RAS) has emerged as a promising objective in biomedical technology, further enhanced by miniaturization toward microrobotic-assisted surgery (μ-RAS). This reduction in scale promises minimally invasive, partially or fully automated surgical procedures, with the potential to reduce patient recovery times, lower medical costs, and enable previously unavailable procedural options. This perspective highlights the specific advances in RAS that potentially map to the microscale (μ-RAS), organized across five surgical domains: endovascular, endoluminal, laparoscopic, ophthalmic, and orthopedic. We examine both clinical demands and technological advances in surgical robotics and identify the key innovations required for progress across these surgical fields. Our contribution is distinct in combining the perspectives of both surgical experts and bioengineering innovators, outlining a roadmap for the advancement and eventual integration of autonomous RAS and μ-RAS into mainstream surgical practice.
Eye Movement and Lid Disorders in Patients With Alternating Hemiplegia of Childhood due to ATP1A3 Gene Variants (P10-17.011)
Al-Abdulghani, Abdulaziz, DeGusmao, Claudio, Brodsky, Michael, Zee, David van der , Kok, Fernando, Castro, Matheus A. A., Mochida, Ganeshwaran H., Rucker, Janet, Al-Abdulghani, Abdulaziz, Brodsky, Michael C., Zee, David, Kok, Fernando , Mochida, Ganeshwaran H.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215936 Get It

The Distinct Role of Family History and Polygenic Risk Scores of Psychiatric Disorders on Lithium Response in Bipolar Disorder
Ercis, Mete , Coombes, Brandon J., Beaupre, Lindsay Melhuish , Solares‐Bravo, Melissa, Moore, Katherine M. , Betcher, Hannah K. , Romo‐Nava, Francisco , Ozerdem, Aysegul, Bond, David J., Prieto, Miguel L. , McElroy, Susan L., Frye, Mark A. , Bond, David J. , Melhuish Beaupre, Lindsay M , Romo-Nava, F , Cuellar-Barboza, Alfredo , Prieto, Miguel L , Frye, Mark , Biernacka, Joanna , Singh, Balwinder , Bond, David J , Ercis, Mete , Coombes, Brandon J. , Solares‐Bravo, Melissa , Veldić, Marin , Ozerdem, Aysegul, Cuéllar‐Barboza, Alfredo B. , McElroy, Susan L. , Biernacka, Joanna M. , Singh, Balwinder

Mayo Clinic

Bipolar Disorders | June 10, 2026 | Volume: 28 | Issue: 4 | Pages: No page available

10.1111/bdi.70126 | PMID 42265849 Get It

ABSTRACT Background This study aimed to explore the effect of family history (FH) and polygenic risk scores (PRS) for multiple psychiatric disorders on lithium response in bipolar disorder (BD). Method The sample included patients from the Mayo Clinic BD Biobank. FH in first‐degree relatives was obtained via the patient questionnaire. Linear regression models tested the association of FH and PRS for BD, major depressive disorder (MDD), schizophrenia (SCZ), alcohol use disorder (AUD), anxiety disorder (ANX), and attention‐deficit/hyperactivity disorder (ADHD) with lithium response measured by the Alda A score adjusted for the Alda B sum score. Post hoc models additionally adjusted for clinical covariates (age at onset, rapid cycling, and BD subtype). Results 716 patients had Alda scores for lithium response (61.9% females, mean age = 43.4 years). FH‐BD ( β = −0.57, p = 0.015), AUD ( β = −0.44, p = 0.045), and ANX ( β = −0.61, p = 0.050) were associated with worse lithium response. After adjusting for clinical covariates, associations for FH‐BD and FH‐ANX were no longer significant. PRS‐BD was associated with better response ( β = 0.22, p = 0.041), while PRS‐MDD ( β = −0.28, p = 0.01) and PRS‐ADHD ( β = −0.24, p = 0.028) were associated with worse response, with effects largely unchanged after adjusting for clinical covariates. In the combined model considering all FHs simultaneously, only FH‐BD remained significantly associated with worse lithium response ( β = −0.71, p = 0.039). In the combined model for PRS, only PRS‐BD ( β = 0.31, p = 0.008; better response) and PRS‐MDD ( β = −0.29, p = 0.020; worse response) showed significant associations. Conclusions In this exploratory study, FH‐BD, AUD, and ANX were associated with poor response, though only FH‐AUD remained significant after adjusting for clinical factors. PRS‐BD predicted better response, while PRS‐MDD was associated with worse response. These findings suggest independent and potentially complementary roles of FH and PRS. Integrating both familial and genetic risk measures may improve personalized treatment strategies and outcomes for BD patients.
Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals
Ni, Zhanmo , Zhong, Jun , McKean, David, Antwi, Samuel O. , Bracci, Paige M., Du, Mengmeng, Gallinger, Steven, Genkinger, Jeanine, Haiman, Christopher A, Hassan, Manal, Huff, Chad , Kooperberg, Charles, Kastrinos, Fay , LeMarchand, Loic, Lee, WP, Oberg, Ann L. , Park, Margaret A. , Permuth, Jennifer B., Risch, Harvey A., Scheet, Paul , Schwartz, Ann, Shu, Xie, Wolpin, Brian M. , Albanes, Demetrius, Andreotti, Gabriella , Beane-Freeman, Laura, Berndt, Sonja I, Brennan, Paul, Buring, Julie E, Cabrera, Natalia, Campa, Daniele, Chanock, Stephen J, Chung, Charles C., Eliassen, A Heather, Gaziano, J. Michael, Giles, G G, Giovannucci, Edward L, Goggins, Michael, Goodman, Phyllis J. , Hicks, Belynda, Hutchinson, Amy , Jones , Katzke, Verena, Kogevinas, Manolis, Kurtz, Robert C. , Laheru, Daniel, Lee, I, Milne, Roger, Mucci, Lorelei, Patel, Alpa V, Peruchet, Laia, Peters, Ulrike, Porta, Miquel, Rabe, Kari G. , Real, Francisco X, Ricceri, Fulvio, Rothman, Nathaniel, Sesso, Howard D. , Setiawan, Veronica W, Debra, Silverman, Southey, M C, Stampfer, M I, Um, Caroline, Visvanathan, Kala, Wentzensen, Nicolas, Willett, Walter C, Kraft, Peter, Visvanathan, Kala , Zhong, Jun , Zheng, Wei , Canzian, Federico , Malats, Nuria , Duggal, Priya , Klein, Alison P , Chaffee, Kari G. , Antwi, Samuel O , Visvanathan, Kala , Vergara, Candelaria , McKean, David , Connelly, Katelyn E. , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng, Genkinger, Jeanine M. , Haiman, Christopher A. , Hung, Rayjean J. , Kooperberg, Charles , Lynch, Shannon M. , Moore, Steven C. , Permuth, Jennifer B. , Risch, Harvey A., Schwartz, Ann, Stolzenberg‐Solomon, Rachael Z. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Berndt, Sonja I. , Brennan, Paul, Buring, Julie E. , Cabrera-Castro, Natalia , Canzian, Federico , Chanock, Stephen Jacob , Chen, Yu , Gaziano, J. Michael , Giovannucci, Edward L. , Goggins, Michael , Hicks, Belynda , Katzke, Verena , Kogevinas, Manolis , Laheru, Daniel A. , Malats, Núria , Milne, Roger, Mucci, Lorelei A. , Neale, Rachel Ε. , Orlow, Irene , Peruchet‐Noray, Laia , Peters, Ulrike , Real, Francisco X. , Ricceri, Fulvio , Rothman, Nathaniel , Setiawan, Veronica Wendy , Silverman, Debra T. , Southey, Melissa C , Stampfer, Meir J. , Tobias, Geoffrey S. , Um, Caroline Y. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yu, Kai , Duggal, Priya , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.21.26351329 | PMID 42078392 Get It

Abstract Pancreatic cancer disproportionately affects Black individuals in the United States, but they have limited representation in genetic studies of pancreatic ductal adenocarcinoma (PDAC). To address this gap, we performed admixture mapping and genome-wide association analysis (GWAS) in genetically inferred African ancestry individuals (1,030 cases and 889 controls). Admixture mapping identified three regions with a significantly higher proportion of African ancestry in cases compared to controls (5q33.3, 10p1, 22q12.3). GWAS identified a genome-wide significant association at 5p15.33 ( CLPTM1L , rs383009:T>C, T Allele Frequency=0.51, OR:1.45, P value=1.24×10 -8 ), a locus previously associated with PDAC. Known loci at 5p15.33, 7q32.3, 8q24.21 and 7q25.1 also replicated (P value <0.01). Multi-ancestral fine-mapping identified two potential causal SNPs (rs3830069 and rs2735940) at 5p15.33. Collectively these findings identified novel PDAC risk loci and expanded our understanding of this deadly cancer in underrepresented populations, emphasizing the multifactorial nature of PDAC risk including inherited genetic and non-genetic factors. Statement of Significance To understand how genetic variation contributes to PDAC risk in Black people in North American, we studied individuals of genetically-inferred African ancestry. We identified novel risk loci and differences in the contribution of known loci. This demonstrates that ancestry-informed genetic analyses improve our understanding of PDAC risk and enhances discovery.
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Imaging solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy human participants
Wen, Xuehua , Sun, Yuanqi, Li, Yinghao, Paez, Adrian , Varghese, Jacob , Knutsson, Linda, Zijl, Peter C.M. Van, Graley, Christina R, Bakker, Arnold, Ward, Bryan K., Kashani, Amir H. , Sun, Yuanqi , Zhou, Xinyi Yedda , Li, Yinghao , Varghese, Jacob, Pillai, Jay J. , Knutsson, Linda , Zijl, Peter C.M. van , Leigh, Richard J. , Kamson, David , Saidha, Shiv , Bakker, Arnold , Ward, Bryan Kevin

Mayo Clinic

No container title available | April 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.03.26349283 | PMID 42006786 Get It

Abstract Background Recently, a posterior pathway for fluid drainage from the retina to the meningeal lymphatics in the optic nerve (ON) sheath was identified in rodents using intravitreal imaging tracers directly injected into the ocular-globe. Fluid and solute clearance along this pathway may be associated with many diseases. However, intravitreal tracers are rarely used in clinical imaging. As intravenous Gadolinium-based-contrast-agent (GBCA) can enter the globe via the blood-ocular-barriers, it may provide an alternative approach to image this pathway. Purpose To establish a clinically feasible intravenous GBCA-based MRI approach for tracking fluid and solute transport along the posterior lymphatic pathway in the ocular glymphatic system. Materials&Methods This prospective study was conducted from March 2021 to September 2022 in healthy participants. Dynamic-susceptibility-contrast-in-the-CSF (cDSC) MRI was performed before, immediately and 4 hours after intravenous-GBCA administration to track GBCA distribution in aqueous humor (AH) and cerebrospinal fluid (CSF) in regions-of-interest (ROIs) in the globe (anterior-cavity, vitreous-body), in the intraorbital and extraorbital ON, and in the intracranial CSF space proximal to the ON (chiasmatic-cistern, interpeduncular-cistern). Kruskal–Wallis tests with post-hoc Dunn’s tests were used for group comparisons. Results Sixteen healthy participants (mean age±SD: 51±21 years, 5 men) were recruited. Intravenous-GBCA enhancement was observed in all ROIs immediately after injection. At 4-hour-post-GBCA, the vitreous body showed a trend of smaller enhancement area (55±11% versus 49±11%, P =.14) and lower GBCA-concentration (0.044±0.014 versus 0.028±0.010 mmol/L, P =.07) compared to immediate-post-GBCA. The intraorbital ON showed more widespread enhancement (39±5% versus 59±6%, P =.01) and significantly higher GBCA-concentration (0.023±0.009 versus 0.059±0.015 mmol/L, P <.001) at 4-hour-post-GBCA. Conclusion Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-GBCAs entering the globe via the blood-ocular-barriers using cDSC-MRI. Summary Statement Dynamic fluid and solute transportation along the posterior lymphatic pathway in the ocular glymphatic system in healthy participants was measured by tracking intravenous-Gadolinium-based-contrast-agents entering ocular-globe via blood-ocular-barriers using dynamic-susceptibility-contrast-in-the-CSF (cDSC)-MRI. Key Results In this prospective study of sixteen participants, Gadolinium-based-contrast-agent (GBCA)-induced signal changes were detected in the aqueous-humor and cerebrospinal fluid immediately following intravenous administration using dynamic-susceptibility-contrast-in-the-CSF (cDSC)-MRI. At 4-hour-post-GBCA, the vitreous-body showed a trend of smaller enhancement area (55±11% versus 49±11%, P =.14) and lower GBCA-concentration (0.044±0.014 versus 0.028±0.010 mmol/L, P =.07) compared to immediate-post-GBCA. The intraorbital-optic-nerve showed more widespread enhancement (39±5% versus 59±6%, P =.01) and higher GBCA-concentration (0.023±0.009 versus 0.059±0.015 mmol/L, P <.001) at 4-hour-post-GBCA.
Evaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors
Grossman, Stuart A. , Barone, Amy , Strowd, Roy E, Rais, Rana , Duke, Elizabeth , Wearne, Emily , Price, Lauren , Hendrix, C. W., Schreck, Karisa C. , Lesser, Glenn J. , Sanai, Nader , Blakeley, Jaishri O, Nabors, Burt L., Sarkaria, Jann N, Peereboom, David, Schiff, D., Prowell, Tatiana M. , Elmquist, William F. , Hendrix, Craig W. , Strowd, Roy E. , Strowd, Roy E , Price, Lauren S L , Hendrix, Craig , Lesser, Glenn , Romo, Carlos , Portnow, Jana , Blakeley, Jaishri O , Kamson, David O , Nabors, Louis Burt , Searson, Peter C , Sarkaria, Jann N , Peereboom, David M , Schiff, David , Prowell, Tatiana M , Grossman, Stuart A , Romo, Carlos G. , Blakeley, Jaishri O. , Kamson, David , Nabors, Burt , Sarkaria, Jann N. , Peereboom, David M.

Mayo Clinic

Neuro-Oncology | March 7, 2026 | Volume: 28 | Issue: 7 | Pages: 1599-1611

10.1093/neuonc/noag051 | PMID 41818680 Get It

Abstract Current assessments of brain permeability rely predominantly on drug delivery to contrast-enhancing tumor regions. However, substantial portions of central nervous system (CNS) tumors reside within non-enhancing brain (NEB), where drug concentrations frequently remain subtherapeutic. This collaborative Adult Brain Tumor Consortium and Food and Drug Administration workshop aimed to identify criteria for defining NEB permeability to accomplish 2 critical objectives: (1) allocate clinical trial resources toward agents achieving therapeutic NEB concentrations and (2) minimize systemic toxicity when CNS benefit is improbable. The workshop systematically evaluated permeability assessment modalities, including drug physicochemical properties, in vitro blood-brain barrier models, and penetration into cerebrospinal fluid and normal rodent brain. Methodological approaches to determine requisite NEB drug concentrations and approaches to measuring NEB pharmacokinetics and pharmacodynamics were examined. This culminated in developing the Non-Enhancing Brain Permeability Index (NEBPI), which assigns therapeutic agents to 3 categories: sufficiently permeable, insufficiently permeable, or impermeable. The NEBPI provides a standardized framework to assist investigators and regulatory agencies to evaluate NEB penetration before human efficacy studies are initiated for agents that require direct tumor contact. Assessing NEB drug penetration is critical to improving outcomes in CNS tumors and reducing the incidence of brain metastases in systemic malignancies.
Dynamic MRI of Fluid and Solute Transportation across the Arachnoid Barrier in the Human Meninges
Li, Yinghao , Sun, Yuanqi, Paez, Adrian , Xu, Gaoqiang , Pillai, Jay J. , Iliff, Jeffrey J., Ganji, Sandeep , Knutsson, Linda, Zijl, Peter C. M. Van, Calabresi, Peter A., Sun, Yuanqi , Knutsson, Linda , Sun, Yang-bai , Sun, Yuanqi , Iliff, Jeffrey , Ganji, Sandeep K , Knutsson, Linda , Calabresi, Peter A , Hua, Jun , Pillai, Jay J , Iliff, Jeffrey J. , Zijl, Peter C.M. van , Kamson, David , Calabresi, Peter A.

Mayo Clinic

Radiology | February 24, 2026 | Volume: 318 | Issue: 2 | Pages: No page available

10.1148/radiol.252393 | PMID 41733473 Get It

Dynamic fluid and solute transportation across the arachnoid barrier in the meninges of healthy participants was measured by tracking intravenous gadolinium-based contrast agent entering cerebrospinal fluid from dural blood vessels using dynamic dual-spin-echo perfusion MRI.